Migraine medicine designed to help prevent attacks*1
AQUIPTA is a simple once-daily tablet that works fast† to prevent migraine1,2
*In 3-month clinical studies, AQUIPTA significantly reduced monthly migraine days.1
†In a clinical study, 87.7% of patients who received AQUIPTA 60 mg did not have a migraine the day after the first dose compared to 74.8% on placebo.2
AQUIPTA® (atogepant) is a prescription medicine that is used to prevent migraine in adults who have at least 4 migraine days per month. It is not funded so it is available only on a private prescription. This means you will need to pay for the medicine, plus any doctor or pharmacy fees.
It is available through selected pharmacies at a special price, with delivery across New Zealand.3
The power of migraine prevention with AQUIPTA
Works fast* to prevent migraine attacks2
*In a clinical study, 87.7% of patients who received AQUIPTA 60 mg did not have a migraine the day after the first dose compared to 74.8% on placebo.2
Fewer monthly migraine days†1
†In 3-month clinical studies, AQUIPTA significantly
reduced monthly migraine days.1
What types of migraine can AQUIPTA help prevent?1
Episodic migraine
Adults who get 4–14 migraine days per month.
Chronic migraine
Adults who experience ≥15 headache days per month with ≥8 migraine days.*
*Monthly headache days refer to any day a headache occurs, while monthly migraine days refer to days that specifically meet the criteria for a migraine attack.
How does AQUIPTA work?3–6
Your body naturally produces a protein called calcitonin gene-related peptide, or CGRP, which is believed to play an important role in migraine attacks.
When CGRP levels rise and bind to the receptors, they can contribute to the pain and inflammation associated with migraine. AQUIPTA works by blocking the CGRP receptors, helping to prevent migraine attacks before they happen.
By taking a tablet once daily, even when you are not experiencing a migraine, you can help keep migraine attacks away. Some people may notice improvements within the first week, while for others, the effects of AQUIPTA may build gradually over 12 weeks or longer.1,2
The person shown is from stock photography (model) and is not an actual patient.
Abbreviation: CGRP, calcitonin gene-related peptide.
References: 1. AQUIPTA® (atogepant) Data Sheet. 2. Schwedt TJ et al. Cephalalgia 2022;42(1):3–11. 3. AQUIPTA® (atogepant) Consumer Medicine Information. 4. Russo AF. Annu Rev Pharmacol Toxicol 2015;55:533–552. 5. Edvinsson L et al. Nat Rev Neurol 2018;14(6):338–350. 6. Edvinsson L. Headache 2017;57(suppl 2):47–55.
NZ-AQP-240017. BG6642. AQU-006007-00. August 2026.
